Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity (Q37089235)

From Wikidata

Jump to navigation Jump to search

scientific article published on 11 August 2009

Language	Label	Description	Also known as
English	Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity	scientific article published on 11 August 2009

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity (English)

1 reference

Europe PubMed Central

18 August 2017

0 references

1 reference

based on heuristic

inferred from title

0 references

DNA mismatch repair

1 reference

based on heuristic

inferred from title

8

object named as

Susan M Blaney

1 reference

Europe PubMed Central

18 August 2017

author name string

Terzah M Horton

1

1 reference

Europe PubMed Central

18 August 2017

Gaye Jenkins

2

1 reference

Europe PubMed Central

18 August 2017

Debananda Pati

3

1 reference

Europe PubMed Central

18 August 2017

Linna Zhang

4

1 reference

Europe PubMed Central

18 August 2017

M Eileen Dolan

5

1 reference

Europe PubMed Central

18 August 2017

Albert Ribes-Zamora

6

1 reference

Europe PubMed Central

18 August 2017

Alison A Bertuch

7

1 reference

Europe PubMed Central

18 August 2017

Shannon L Delaney

9

1 reference

Europe PubMed Central

18 August 2017

Madhuri Hegde

10

1 reference

Europe PubMed Central

18 August 2017

Stacey L Berg

11

1 reference

Europe PubMed Central

18 August 2017

publication date

11 August 2009

1 reference

Europe PubMed Central

18 August 2017

Molecular Cancer Therapeutics

1 reference

Europe PubMed Central

18 August 2017

8

1 reference

Europe PubMed Central

18 August 2017

8

1 reference

Europe PubMed Central

18 August 2017

2232-2242

1 reference

Europe PubMed Central

18 August 2017

describes a project that uses

1 reference

Europe PubMed Central

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC3741063/fullTextXML

based on heuristic

inferred from PubMed Central ID database lookup

Small-scale extracts for the study of nucleotide excision repair and non-homologous end joining

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Bortezomib interactions with chemotherapy agents in acute leukemia in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

PARP inhibitors for cancer therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Hormone-induced chromosomal instability in p53-null mammary epithelium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Mismatch repair deficiency in hematological malignancies with microsatellite instability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Temozolomide and treatment of malignant glioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

O6 alkylguanine-DNA alkyltransferase activity in human myeloid cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

29 September 2017

Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

27 June 2018

Frameshift mutations of the hMSH6 gene in human leukemia cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

27 July 2018

Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

3 September 2018

Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

3 September 2018

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

3 September 2018

Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

3 September 2018

Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

3 September 2018

Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

3 September 2018

Phase I study of temozolomide in relapsed/refractory acute leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

3 September 2018

Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3741063

3 September 2018

Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19671751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Microsatellite instability and cytogenetic survey in myeloid leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/19671751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/19671751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mutations and loss of expression of a mismatch repair gene, hMLH1, in leukemia and lymphoma cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/19671751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings

1 reference

https://pubmed.ncbi.nlm.nih.gov/19671751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase

1 reference

https://pubmed.ncbi.nlm.nih.gov/19671751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/19671751

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1535-7163.MCT-09-0142

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37089235&oldid=2086109708"